Physician profile
Michael Lee
NPI 1255373346
$2,831.02
in general payments reported to CMS, 2019-2025
24 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $76.38 · 2021: $92.25 · 2022: $146 · 2023: $1,016 · 2024: $178 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $301.84 | 2019-2025 | |
| Tepha INC | $292.26 | 2019-2020 | |
| Calyxo, INC. | $276.36 | 2025 | Cvac Aspiration System |
| Innovation Technologies INC | $253.73 | 2023 | Irrisept |
| Astellas Pharma US INC | $211.71 | 2019-2021 | |
| Boston Scientific Corporation | $204.79 | 2020-2024 | Advantage System, Ams 700 Cxr Rte Kit |
| Olympus America INC. | $175.24 | 2023-2025 | Itind System |
| Baxter Healthcare | $142.65 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $142.05 | 2023 | Lynparza |
| Endo Pharmaceuticals INC. | $141.58 | 2023 | Xiaflex, Aveed |
| Travere Therapeutics, INC. | $139.73 | 2019 | |
| Laborie Medical Technologies Corp. | $119.29 | 2025 | |
| Merck Sharp & Dohme LLC | $74.29 | 2022-2023 | Welireg, Lynparza, Keytruda |
| Myovant Sciences INC. | $69.76 | 2021-2022 | |
| Glaxosmithkline, LLC. | $56.00 | 2022-2025 | Bexsero |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih Ab | $45.38 | 2023-2024 | Lofric, Lofric |
| Abbvie INC. | $28.52 | 2022 | |
| Tolmar, INC. | $28.41 | 2023 | |
| Sumitomo Pharma America, INC. | $27.73 | 2023 | Orgovyx |
| Urogen Pharma, INC. | $27.22 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2019 | |
| Atricure, INC. | $19.16 | 2024 | |
| Amgen INC. | $18.13 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $15.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.